Palovarotene Patent Expiration

Palovarotene is Used for reducing heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva. It was first introduced by Ipsen Biopharmaceuticals Inc in its drug Sohonos on Aug 16, 2023.


Palovarotene Patents

Given below is the list of patents protecting Palovarotene, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sohonos US10292954 Composition and method for muscle repair and regeneration Aug 31, 2031 Ipsen
Sohonos US10864194 Methods for treating heterotopic ossification Jun 08, 2037 Ipsen
Sohonos US11622959 Methods for treating heterotopic ossification Jun 08, 2037 Ipsen
Sohonos US9314439 Composition and method for muscle repair and regeneration Aug 31, 2031 Ipsen
Sohonos US9789074 Composition and method for muscle repair and regeneration Aug 31, 2031 Ipsen


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Palovarotene's patents.

Given below is the list recent legal activities going on the following patents of Palovarotene.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 29 May, 2024 US10864194
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US9314439
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US10292954
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US11622959
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US10864194
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US11622959
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US10864194
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US10292954
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US9314439
Initial letter Re: PTE Application to regulating agency 22 Nov, 2023 US10292954



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳